CClinicalTrials.gg
CompletedNCT04810065ssUpdated Sep 28, 2021

SingStrong: Strong Lungs Through Song - Long COVID-19 Study

An interventional study of SingStrong: Strong lungs through Song in Long Covid, sponsored by University of Limerick. Completed at 1 site in Ireland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-28.

Sponsored by University of Limerick · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Evidence is emerging that many individuals who recover from Covid-19 are experiencing a range of residual problems. These include fatigue, pain, reduced exercise tolerance and breathing issues. This study includes participants who are experiencing problems with their lungs such as breathing difficulties, shortness of breath, and/or reduced exercise tolerance. The intervention is a twice weekly singing and breathing retraining intervention conducted over ten weeks. A range of self-report questionnaire measures will evaluate the efficacy of the intervention in addressing these problems. Focus groups and individual interviews will also be used to gather information on the impact and acceptability of the programme.

02

Conditions studied

  • Long Covid

Keywords

  • Singing
  • Disordered breathing
  • Covid-19
03

In context

Post-Acute COVID-19 Syndrome

520 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 186 are open to participants now.

This study's enrollment of 30 is below the median of 60 across 361 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

University of Limerick is the lead sponsor of 56 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years of age or older
  • Previous clinical diagnosis of Covid-19
  • Ongoing issues with any or all of: Shortness of breath, disordered breathing, reduced exercise tolerance
  • Good written and spoken English language

Exclusion criteria

Exclusion Criteria:

  • Lack of a confirmed Covid-19 diagnosis
  • Currently undergoing a similar singing or breathing retraining intervention
  • No residual problems from a confirmed case of Covid-19
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    SingStrong for Pulmonary Fibrosis

    This arm of the project explores Singing as an intervention for people suffering from Pulmonary Fibrosis specifically. It is a 10 week programme. All other aspects of the intervention are the same in terms of delivery and length of classes. Different outcome measures, namely the St Georges Respiratory Questionnaire is used in this trial. This is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.

    Other: SingStrong: Strong lungs through Song

Interventions

  • OtherSingStrong: Strong lungs through Song

    Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study. The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration. Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,

06

What researchers measure

Primary outcomes

  1. Covid-19 Yorkshire Rehab Screen (C19YRS)

    The C19YRS was developed as a screening tool to monitor long-term symptoms due to Covid-19. The screening tool covers 19 items which combines yes/no answers and an 11 point ordinal scale (0-10) where a higher score denotes increased symptom severity.

    Time frame: 12 weeks

Secondary outcomes

  1. DePaul Symptom Questionnaire - Short Form DSQ - SF

    The DPSQ -SF assesses key symptoms of ME/Chronic Fatigue Syndrome such as fatigue, post-exertional malaise, sleep, pain, neurological/cognitive impairments and autonomic, neuroendocrine and immune symptoms. At each item, participants have to rate the frequency and severity of the symptom on a scale from 0 to 4. A higher score denotes increased symptom severity.

    Time frame: 12 weeks

07

Study locations

1 site
  • University of Limerick
    Limerick, Ireland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04810065
Lead sponsor
University of Limerick
Responsible party
Roisin Cahalan (Senior Lecturer Physiotherapy, University of Limerick) — Principal investigator
First posted
Mar 22, 2021
Start date
Mar 29, 2021
Primary completion
Jul 29, 2021
Completion
Sep 1, 2021
Last update
Sep 28, 2021

Study contacts

Roisin Cahalan, PhD
principal investigator · University of Limerick

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion